Education
About Us
Working with TipRanks
Follow Us
Cyclopharm Limited (AU:CYC)
ASX:CYC
Total Valuation
Cyclopharm Limited has a market cap or net worth of AU$80.94M. The enterprise value is AU$89.23M.
Market CapAU$80.94M
Enterprise ValueAU$89.23M
Share Statistics
Cyclopharm Limited has 120,802,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding120,802,630
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cyclopharm Limited’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -49.53%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.37
Return on Invested Capital (ROIC)-49.53%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee340.27K
Profits Per Employee-181.26K
Employee Count95
Asset Turnover0.70
Inventory Turnover2.95
Valuation Ratios
The current PE Ratio of Cyclopharm Limited is ―. Cyclopharm Limited’s PEG ratio is -0.27.
PE Ratio―
PS Ratio3.34
PB Ratio3.98
Price to Fair Value3.98
Price to FCF-5.59
Price to Operating Cash Flow-4.25
PEG Ratio-0.27
Income Statement
In the last 12 months, Cyclopharm Limited had revenue of 32.33M and earned -17.22M in profits. Earnings per share was -0.16.
Revenue32.33M
Gross Profit-1.46M
Operating Income-18.18M
Pretax Income-17.86M
Net Income-17.22M
EBITDA-16.41M
Earnings Per Share (EPS)-0.16
Cash Flow
In the last 12 months, operating cash flow was -17.33M and capital expenditures -1.99M, giving a free cash flow of -19.32M billion.
Operating Cash Flow-17.33M
Free Cash Flow-19.32M
Free Cash Flow per Share-0.16
Dividends & Yields
Cyclopharm Limited pays an annual dividend of AU$0.008, resulting in a dividend yield of ―
Dividend Per ShareAU$0.008
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change-53.15%
50-Day Moving Average0.91
200-Day Moving Average0.90
Relative Strength Index (RSI)32.58
Average Volume (3m)97.64K
Important Dates
Cyclopharm Limited upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Cyclopharm Limited as a current ratio of 2.53, with Debt / Equity ratio of 55.04%
Current Ratio2.53
Quick Ratio1.51
Debt to Market Cap0.07
Net Debt to EBITDA-0.51
Interest Coverage Ratio-29.03
Taxes
In the past 12 months, Cyclopharm Limited has paid -636.78K in taxes.
Income Tax-636.78K
Effective Tax Rate0.04
Enterprise Valuation
Cyclopharm Limited EV to EBITDA ratio is -7.08, with an EV/FCF ratio of -6.02.
EV to Sales3.60
EV to EBITDA-7.08
EV to Free Cash Flow-6.02
EV to Operating Cash Flow-6.71
Balance Sheet
Cyclopharm Limited has AU$6.63M in cash and marketable securities with AU$14.92M in debt, giving a net cash position of -AU$8.29M billion.
Cash & Marketable SecuritiesAU$6.63M
Total DebtAU$14.92M
Net Cash-AU$8.29M
Net Cash Per Share-AU$0.07
Tangible Book Value Per ShareAU$0.22
Margins
Gross margin is 24.11%, with operating margin of -56.25%, and net profit margin of -53.27%.
Gross Margin24.11%
Operating Margin-56.25%
Pretax Margin-55.24%
Net Profit Margin-53.27%
EBITDA Margin-50.77%
EBIT Margin-56.25%
Analyst Forecast
The average price target for Cyclopharm Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast34.20%
EPS Growth Forecast-23.90%